Form 4: ProMIS Neurosciences Director Receives Option Grant
Statement of Changes in Beneficial Ownership
Director Eugene Williams was granted options to purchase 16,500 common shares of ProMIS Neurosciences Inc.
Summary
- Director Eugene Williams received two separate option grants totaling 16,500 shares of ProMIS Neurosciences Inc. (PMN).
- The options have an exercise price of $10.77 per share.
- The grants consist of 5,500 shares vesting in full on May 20, 2027, and 11,000 shares with 25% vesting immediately and the remainder vesting ratably over 36 months.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention mechanism established through multi-year vesting schedules.
Negatives
- Potential for future dilution of existing shareholders upon the exercise of these options.
Risks
- Continued service on the Board is required for the vesting of these options.
- Market price volatility may impact the future value of the granted options.
Future Outlook
The options are subject to continued service on the Board, with vesting periods extending through May 2027 and beyond.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership alignment with long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of time-based vesting for director compensation is consistent with standard corporate governance practices in the biotech industry.
- The exercise price reflects the market valuation at the time of the grant, aligning with typical equity incentive plan structures.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of 25% of the 11,000 share grant occurred on May 20, 2026.
- Continued service on the Board required for remaining vesting.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of grant for the stock options. |
| 05/20/2027 | Full vesting date for the 5,500 share option grant. |
| 05/20/2036 | Expiration date for the granted stock options. |
Keywords
ProMIS Neurosciences, PMN, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.